PIRCHE-II Is Related to Graft Failure after Kidney Transplantation

Kirsten Geneugelijk; Matthias Niemann; Julia Drylewicz; Arjan D. van Zuilen; Irma Joosten; Wil A. Allebes; Arnold van der Meer; Luuk B. Hilbrands; Marije C. Baas; C. Erik Hack; Franka E. van Reekum; Marianne C. Verhaar; Elena G. Kamburova; Michiel L. Bots; Marc A. J. Seelen; Jan Stephan Sanders; Bouke G. Hepkema; Annechien J. Lambeck; Laura B. Bungener; Caroline Roozendaal; Marcel G. J. Tilanus; Joris Vanderlocht; Christien E. Voorter; Lotte Wieten; Elly M. van Duijnhoven; Marielle Gelens; Maarten H. L. Christiaans; Frans J. van Ittersum; Azam Nurmohamed; Junior N. M. Lardy; Wendy Swelsen; Karlijn A. van der Pant; Neelke C. van der Weerd; Ineke J. M. ten Berge; Frederike J. Bemelman; Andries Hoitsma; Paul J. M. van der Boog; Johan W. de Fijter; Michiel G. H. Betjes; Sebastiaan Heidt; Dave L. Roelen; Frans H. Claas; Henny G. Otten; Eric Spierings

doi:10.3389/fimmu.2018.00321

PIRCHE-II Is Related to Graft Failure after Kidney Transplantation

Kirsten Geneugelijk, Matthias Niemann, Julia Drylewicz, Arjan D. van Zuilen, Irma Joosten, Wil A. Allebes, Arnold van der Meer, Luuk B. Hilbrands, Marije C. Baas, C. Erik Hack, Franka E. van Reekum, Marianne C. Verhaar, Elena G. Kamburova, Michiel L. Bots, Marc A. J. Seelen, Jan Stephan Sanders, Bouke G. Hepkema, Annechien J. Lambeck, Laura B. Bungener, Caroline RoozendaalMarcel G. J. Tilanus, Joris Vanderlocht, Christien E. Voorter, Lotte Wieten, Elly M. van Duijnhoven, Marielle Gelens, Maarten H. L. Christiaans, Frans J. van Ittersum, Azam Nurmohamed, Junior N. M. Lardy, Wendy Swelsen, Karlijn A. van der Pant, Neelke C. van der Weerd, Ineke J. M. ten Berge, Frederike J. Bemelman, Andries Hoitsma, Paul J. M. van der Boog, Johan W. de Fijter, Michiel G. H. Betjes, Sebastiaan Heidt, Dave L. Roelen, Frans H. Claas, Henny G. Otten, Eric Spierings^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Individual HLA mismatches may differentially impact graft survival after kidney trans plantation. Therefore, there is a need for a reliable tool to define permissible HLA mismatches in kidney transplantation. We previously demonstrated that donor-derived Predicted Indirectly ReCognizable HLA Epitopes presented by recipient HLA class II (PIRCHE-II) play a role in de novo donor-specific HLA antibodies formation after kidney transplantation. In the present Dutch multi-center study, we evaluated the possible association between PIRCHE-II and kidney graft failure in 2,918 donor-recipient couples that were transplanted between 1995 and 2005. For these donors-recipients couples, PIRCHE-II numbers were related to graft survival in univariate and multivariable analyses. Adjusted for confounders, the natural logarithm of PIRCHE-II was associated with a higher risk for graft failure [hazard ratio (HR): 1.13, 95% CI: 1.04-1.23, p = 0.003]. When analyzing a subgroup of patients who had their first transplantation, the HR of graft failure for In(PIRCHE-II) was higher compared with the overall cohort (HR: 1.22, 95% CI: 1.10-1.34, p < 0.001). PIRCHE-II demonstrated both early and late effects on graft failure in this subgroup. These data suggest that the PIRCHE-II may impact graft survival after kidney transplantation. Inclusion of PIRCHE-II in donor-selection criteria may eventually lead to an improved kidney graft survival.

Original language	English
Article number	321
Number of pages	9
Journal	Frontiers in Immunology
Volume	9
Issue number	MAR
DOIs	https://doi.org/10.3389/fimmu.2018.00321
Publication status	Published - 5 Mar 2018

Keywords

PIRCHE-II
kidney transplantation
graft rejection
HLA antigens
HLA matching
MOLECULARLY BASED ALGORITHM
HISTOCOMPATIBILITY DETERMINATION
HLA ANTIBODIES
REJECTION
ANTIGEN
IMMUNOGENICITY
HLAMATCHMAKER
COMPATIBILITY
ASSOCIATION
MISMATCHES

Access to Document

10.3389/fimmu.2018.00321Licence: CC BY

https://www.frontiersin.org/articles/10.3389/fimmu.2018.00321/pdf

Cite this

Geneugelijk, K., Niemann, M., Drylewicz, J., van Zuilen, A. D., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Hack, C. E., van Reekum, F. E., Verhaar, M. C., Kamburova, E. G., Bots, M. L., Seelen, M. A. J., Sanders, J. S., Hepkema, B. G., Lambeck, A. J., Bungener, L. B., ... Spierings, E. (2018). PIRCHE-II Is Related to Graft Failure after Kidney Transplantation. Frontiers in Immunology, 9(MAR), Article 321. https://doi.org/10.3389/fimmu.2018.00321

@article{689e9431e7d740a99208e0306ddca4bf,

title = "PIRCHE-II Is Related to Graft Failure after Kidney Transplantation",

abstract = "Individual HLA mismatches may differentially impact graft survival after kidney trans plantation. Therefore, there is a need for a reliable tool to define permissible HLA mismatches in kidney transplantation. We previously demonstrated that donor-derived Predicted Indirectly ReCognizable HLA Epitopes presented by recipient HLA class II (PIRCHE-II) play a role in de novo donor-specific HLA antibodies formation after kidney transplantation. In the present Dutch multi-center study, we evaluated the possible association between PIRCHE-II and kidney graft failure in 2,918 donor-recipient couples that were transplanted between 1995 and 2005. For these donors-recipients couples, PIRCHE-II numbers were related to graft survival in univariate and multivariable analyses. Adjusted for confounders, the natural logarithm of PIRCHE-II was associated with a higher risk for graft failure [hazard ratio (HR): 1.13, 95% CI: 1.04-1.23, p = 0.003]. When analyzing a subgroup of patients who had their first transplantation, the HR of graft failure for In(PIRCHE-II) was higher compared with the overall cohort (HR: 1.22, 95% CI: 1.10-1.34, p < 0.001). PIRCHE-II demonstrated both early and late effects on graft failure in this subgroup. These data suggest that the PIRCHE-II may impact graft survival after kidney transplantation. Inclusion of PIRCHE-II in donor-selection criteria may eventually lead to an improved kidney graft survival.",

keywords = "PIRCHE-II, kidney transplantation, graft rejection, HLA antigens, HLA matching, MOLECULARLY BASED ALGORITHM, HISTOCOMPATIBILITY DETERMINATION, HLA ANTIBODIES, REJECTION, ANTIGEN, IMMUNOGENICITY, HLAMATCHMAKER, COMPATIBILITY, ASSOCIATION, MISMATCHES",

author = "Kirsten Geneugelijk and Matthias Niemann and Julia Drylewicz and {van Zuilen}, {Arjan D.} and Irma Joosten and Allebes, {Wil A.} and {van der Meer}, Arnold and Hilbrands, {Luuk B.} and Baas, {Marije C.} and Hack, {C. Erik} and {van Reekum}, {Franka E.} and Verhaar, {Marianne C.} and Kamburova, {Elena G.} and Bots, {Michiel L.} and Seelen, {Marc A. J.} and Sanders, {Jan Stephan} and Hepkema, {Bouke G.} and Lambeck, {Annechien J.} and Bungener, {Laura B.} and Caroline Roozendaal and Tilanus, {Marcel G. J.} and Joris Vanderlocht and Voorter, {Christien E.} and Lotte Wieten and {van Duijnhoven}, {Elly M.} and Marielle Gelens and Christiaans, {Maarten H. L.} and {van Ittersum}, {Frans J.} and Azam Nurmohamed and Lardy, {Junior N. M.} and Wendy Swelsen and {van der Pant}, {Karlijn A.} and {van der Weerd}, {Neelke C.} and {ten Berge}, {Ineke J. M.} and Bemelman, {Frederike J.} and Andries Hoitsma and {van der Boog}, {Paul J. M.} and {de Fijter}, {Johan W.} and Betjes, {Michiel G. H.} and Sebastiaan Heidt and Roelen, {Dave L.} and Claas, {Frans H.} and Otten, {Henny G.} and Eric Spierings",

year = "2018",

month = mar,

day = "5",

doi = "10.3389/fimmu.2018.00321",

language = "English",

volume = "9",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media S.A.",

number = "MAR",

}

Geneugelijk, K, Niemann, M, Drylewicz, J, van Zuilen, AD, Joosten, I, Allebes, WA, van der Meer, A, Hilbrands, LB, Baas, MC, Hack, CE, van Reekum, FE, Verhaar, MC, Kamburova, EG, Bots, ML, Seelen, MAJ, Sanders, JS, Hepkema, BG, Lambeck, AJ, Bungener, LB, Roozendaal, C, Tilanus, MGJ, Vanderlocht, J, Voorter, CE , Wieten, L , van Duijnhoven, EM , Gelens, M , Christiaans, MHL, van Ittersum, FJ, Nurmohamed, A, Lardy, JNM, Swelsen, W, van der Pant, KA, van der Weerd, NC, ten Berge, IJM, Bemelman, FJ, Hoitsma, A, van der Boog, PJM, de Fijter, JW, Betjes, MGH, Heidt, S, Roelen, DL, Claas, FH, Otten, HG & Spierings, E 2018, 'PIRCHE-II Is Related to Graft Failure after Kidney Transplantation', Frontiers in Immunology, vol. 9, no. MAR, 321. https://doi.org/10.3389/fimmu.2018.00321

TY - JOUR

T1 - PIRCHE-II Is Related to Graft Failure after Kidney Transplantation

AU - Geneugelijk, Kirsten

AU - Niemann, Matthias

AU - Drylewicz, Julia

AU - van Zuilen, Arjan D.

AU - Joosten, Irma

AU - Allebes, Wil A.

AU - van der Meer, Arnold

AU - Hilbrands, Luuk B.

AU - Baas, Marije C.

AU - Hack, C. Erik

AU - van Reekum, Franka E.

AU - Verhaar, Marianne C.

AU - Kamburova, Elena G.

AU - Bots, Michiel L.

AU - Seelen, Marc A. J.

AU - Sanders, Jan Stephan

AU - Hepkema, Bouke G.

AU - Lambeck, Annechien J.

AU - Bungener, Laura B.

AU - Roozendaal, Caroline

AU - Tilanus, Marcel G. J.

AU - Vanderlocht, Joris

AU - Voorter, Christien E.

AU - Wieten, Lotte

AU - van Duijnhoven, Elly M.

AU - Gelens, Marielle

AU - Christiaans, Maarten H. L.

AU - van Ittersum, Frans J.

AU - Nurmohamed, Azam

AU - Lardy, Junior N. M.

AU - Swelsen, Wendy

AU - van der Pant, Karlijn A.

AU - van der Weerd, Neelke C.

AU - ten Berge, Ineke J. M.

AU - Bemelman, Frederike J.

AU - Hoitsma, Andries

AU - van der Boog, Paul J. M.

AU - de Fijter, Johan W.

AU - Betjes, Michiel G. H.

AU - Heidt, Sebastiaan

AU - Roelen, Dave L.

AU - Claas, Frans H.

AU - Otten, Henny G.

AU - Spierings, Eric

PY - 2018/3/5

Y1 - 2018/3/5

N2 - Individual HLA mismatches may differentially impact graft survival after kidney trans plantation. Therefore, there is a need for a reliable tool to define permissible HLA mismatches in kidney transplantation. We previously demonstrated that donor-derived Predicted Indirectly ReCognizable HLA Epitopes presented by recipient HLA class II (PIRCHE-II) play a role in de novo donor-specific HLA antibodies formation after kidney transplantation. In the present Dutch multi-center study, we evaluated the possible association between PIRCHE-II and kidney graft failure in 2,918 donor-recipient couples that were transplanted between 1995 and 2005. For these donors-recipients couples, PIRCHE-II numbers were related to graft survival in univariate and multivariable analyses. Adjusted for confounders, the natural logarithm of PIRCHE-II was associated with a higher risk for graft failure [hazard ratio (HR): 1.13, 95% CI: 1.04-1.23, p = 0.003]. When analyzing a subgroup of patients who had their first transplantation, the HR of graft failure for In(PIRCHE-II) was higher compared with the overall cohort (HR: 1.22, 95% CI: 1.10-1.34, p < 0.001). PIRCHE-II demonstrated both early and late effects on graft failure in this subgroup. These data suggest that the PIRCHE-II may impact graft survival after kidney transplantation. Inclusion of PIRCHE-II in donor-selection criteria may eventually lead to an improved kidney graft survival.

AB - Individual HLA mismatches may differentially impact graft survival after kidney trans plantation. Therefore, there is a need for a reliable tool to define permissible HLA mismatches in kidney transplantation. We previously demonstrated that donor-derived Predicted Indirectly ReCognizable HLA Epitopes presented by recipient HLA class II (PIRCHE-II) play a role in de novo donor-specific HLA antibodies formation after kidney transplantation. In the present Dutch multi-center study, we evaluated the possible association between PIRCHE-II and kidney graft failure in 2,918 donor-recipient couples that were transplanted between 1995 and 2005. For these donors-recipients couples, PIRCHE-II numbers were related to graft survival in univariate and multivariable analyses. Adjusted for confounders, the natural logarithm of PIRCHE-II was associated with a higher risk for graft failure [hazard ratio (HR): 1.13, 95% CI: 1.04-1.23, p = 0.003]. When analyzing a subgroup of patients who had their first transplantation, the HR of graft failure for In(PIRCHE-II) was higher compared with the overall cohort (HR: 1.22, 95% CI: 1.10-1.34, p < 0.001). PIRCHE-II demonstrated both early and late effects on graft failure in this subgroup. These data suggest that the PIRCHE-II may impact graft survival after kidney transplantation. Inclusion of PIRCHE-II in donor-selection criteria may eventually lead to an improved kidney graft survival.

KW - PIRCHE-II

KW - kidney transplantation

KW - graft rejection

KW - HLA antigens

KW - HLA matching

KW - MOLECULARLY BASED ALGORITHM

KW - HISTOCOMPATIBILITY DETERMINATION

KW - HLA ANTIBODIES

KW - REJECTION

KW - ANTIGEN

KW - IMMUNOGENICITY

KW - HLAMATCHMAKER

KW - COMPATIBILITY

KW - ASSOCIATION

KW - MISMATCHES

U2 - 10.3389/fimmu.2018.00321

DO - 10.3389/fimmu.2018.00321

M3 - Article

C2 - 29556227

SN - 1664-3224

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

IS - MAR

M1 - 321

ER -

PIRCHE-II Is Related to Graft Failure after Kidney Transplantation

Abstract

Keywords

Access to Document

Fingerprint

Cite this